Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SRTS 
Sensus Healthcare Inc (SRTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: SRTS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.77% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 73.57M USD | Price to earnings Ratio 10.88 | 1Y Target Price 12 |
Price to earnings Ratio 10.88 | 1Y Target Price 12 | ||
Volume (30-day avg) 145413 | Beta 1.11 | 52 Weeks Range 3.09 - 9.33 | Updated Date 04/7/2025 |
52 Weeks Range 3.09 - 9.33 | Updated Date 04/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.9% | Operating Margin (TTM) 40.84% |
Management Effectiveness
Return on Assets (TTM) 8.73% | Return on Equity (TTM) 12.7% |
Valuation
Trailing PE 10.88 | Forward PE 13.66 | Enterprise Value 51785558 | Price to Sales(TTM) 1.76 |
Enterprise Value 51785558 | Price to Sales(TTM) 1.76 | ||
Enterprise Value to Revenue 1.24 | Enterprise Value to EBITDA 6.08 | Shares Outstanding 16495400 | Shares Floating 13666711 |
Shares Outstanding 16495400 | Shares Floating 13666711 | ||
Percent Insiders 17.75 | Percent Institutions 30.72 |
Analyst Ratings
Rating 4.25 | Target Price 11.5 | Buy 3 | Strong Buy 1 |
Buy 3 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sensus Healthcare Inc
Company Overview
History and Background
Sensus Healthcare Inc. was founded in 2010. It focuses on developing and commercializing non-invasive and minimally-invasive medical devices utilizing superficial radiation therapy (SRT) for treating skin conditions, including non-melanoma skin cancers and keloids.
Core Business Areas
- SRT Systems: Designs, manufactures, and markets SRT systems, primarily the SRT-100 product line.
- Treatment Services: Provides SRT treatment services through partnerships and direct operations.
- Microdermabrasion: Offers a microdermabrasion system used for skin resurfacing.
Leadership and Structure
Joe Sardano is the current CEO and Chairman. The organizational structure includes departments for sales, marketing, R&D, operations, and finance.
Top Products and Market Share
Key Offerings
- SRT-100 Vision: The SRT-100 Vision is Sensus Healthcare's primary product, a superficial radiation therapy system. Market share for SRT in non-melanoma skin cancer treatment is growing, but difficult to pinpoint an exact number. Competitors include Accuray (CyberKnife for skin lesions) and Elekta (though less direct competition). Limited market data available, but SRT-100 contributes the majority of revenue.
- SRT-100: Earlier version of SRT product line. Still in use, though new systems being pushed to newer technologies. Competition remains the same as the SRT-100 Vision. Limited market data available, but SRT-100 contributes to a portion of revenue.
- TransDermal Infusion System: A device that facilitates drug delivery. Contributes a smaller portion of the overall revenue. Competition: Various companies making similar devices.
Market Dynamics
Industry Overview
The medical device industry is characterized by rapid technological advancements and intense competition. The dermatology segment is driven by aging populations, increasing skin cancer rates, and growing demand for aesthetic procedures.
Positioning
Sensus Healthcare is positioned as a leader in SRT for non-melanoma skin cancer and keloid treatment, offering a non-surgical alternative. Competitive advantages include its proprietary technology and established market presence.
Total Addressable Market (TAM)
The total addressable market for non-melanoma skin cancer treatment is substantial, estimated at several billion dollars annually. Sensus Healthcare is positioned to capture a portion of this market through its SRT technology, although the exact percentage is difficult to estimate due to the diverse treatment options available.
Upturn SWOT Analysis
Strengths
- Proprietary SRT technology
- Established market presence in SRT
- Non-invasive treatment alternative
- Growing adoption of SRT
Weaknesses
- Reliance on a single product line (SRT-100)
- Relatively small market capitalization
- Competition from other treatment modalities (surgery, topical creams)
- Sensitivity to reimbursement changes
Opportunities
- Expanding applications of SRT (e.g., keloid treatment)
- Increasing awareness of SRT benefits
- Geographic expansion (international markets)
- Strategic partnerships
Threats
- Technological advancements in competing treatments
- Changes in reimbursement policies
- Increased competition from larger medical device companies
- Economic downturn affecting capital equipment purchases
Competitors and Market Share
Key Competitors
- ACUR
- ELEK
- Varian Medical Systems (Now Part of Siemens Healthineers but not a US-based stock)
Competitive Landscape
Sensus Healthcare competes with larger medical device companies. Advantages include its focus on SRT and specialized expertise. Disadvantages include limited resources compared to larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Discuss revenue growth rates, market share gains, and expansion into new markets. Identify key drivers of historical growth.
Future Projections: Based on analyst estimates, project future revenue growth, profitability, and EPS. Consider market trends, competition, and company-specific initiatives.
Recent Initiatives: Highlight recent product launches, partnerships, acquisitions, and strategic investments.
Summary
Sensus Healthcare is a niche player in the medical device industry, focusing on SRT for dermatological conditions. The company's strength lies in its proprietary technology and established presence in the SRT market. However, its reliance on a single product line and competition from larger companies pose challenges. Future growth depends on expanding SRT applications and geographic reach.
Similar Companies
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q)
- Company press releases
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is subject to change and may not be entirely accurate. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sensus Healthcare Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2016-06-03 | Co-Founder, Chairman & CEO Mr. Joseph C. Sardano | ||
Sector Healthcare | Industry Medical Devices | Full time employees 54 | Website https://sensushealthcare.com |
Full time employees 54 | Website https://sensushealthcare.com | ||
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.